Category: Antibody Humanization

Novel Antibody Therapies: Current Scenario and Future Potential

Novel antibody therapies are chimeric proteins having antibodies attached lethal effector molecules. Currently, six of these therapies are commercially available, while around 140 molecules are under development majorly for oncological disorders. Multiple novel antibody formats have been engineered to enhance therapeutic efficacy. This has opened a new target space for the development of antibody therapeutics

Fc Fusion Protein – A New Approach to Drug Therapy

Since the approval of Enbrel®, CD4 – Fc fusion protein (for the treatment of rheumatoid arthritis) in 1998, Fc fusion protein therapies have evolved into a prominent class of therapeutics. Currently, 13 Fc fusion protein based drugs are commercially available, while around 50 molecules are under development for various disease indications. Some of the Fc fusion

ADC Therapeutics – Alternative to Traditional Anticancer Therapies

Antibody-drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have captured the attention of both large and small pharmaceutical companies, and academic / research institutions from all across the world. Fundamentally, these complex biotherapeutic entities demonstrate the combination of target specificity of an antibody and therapeutic features of a chemotherapy / cytotoxic

Antibody Humanization and Affinity Maturation: Current Market Landscape and Opportunity Areas

Certain steps of antibody drug discovery require advanced expertise, and companies offering these specialized services have attracted significant attention of drug / therapy developers. Two such specific services are to reduce antibody immunogenicity (humanization) and enhance its affinity (affinity maturation). The ‘Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030’ report provides a comprehensive view on the current landscape and the